Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAJAT KIRAN DHAR

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1023073277
CMS profile
272954
Location
GLENDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$4,774.24

134 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,203.75 128
Travel and Lodging $1,470.50 5
Education $99.99 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAJAT KIRAN DHAR

NPI 1023073277 · CMS profile ID 272954

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

GLENDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023073277?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAJAT KIRAN DHAR, NPI 1023073277, CMS profile ID 272954. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023073277?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). RAJAT KIRAN DHAR, NPI 1023073277, CMS profile ID 272954. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023073277?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
RAJAT KIRAN DHAR, NPI 1023073277, CMS profile ID 272954, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1023073277?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

134 matching records · $4,774.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 134 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–134 of 134.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $28.1005/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228276469 CMS
Janssen Biotech, Inc. $20.5505/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174471215 CMS
Janssen Biotech, Inc. $26.3805/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174470725 CMS
Novartis Pharmaceuticals Corporation $157.0705/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200157744 CMS
Novartis Pharmaceuticals Corporation $575.5705/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200157750 CMS
Novartis Pharmaceuticals Corporation $244.6505/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200157748 CMS
Novartis Pharmaceuticals Corporation $140.0005/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200157746 CMS
GENZYME CORPORATION $23.8105/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233522949 CMS
Fresenius Kabi USA, LLC $27.7504/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250520645 CMS
ABBVIE INC. $18.2404/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201760716 CMS
SOBI, INC $27.0604/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240225227 CMS
Organon LLC $21.7004/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237638512 CMS
ABBVIE INC. $21.7604/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201760714 CMS
Amgen Inc. $8.2104/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227048722 CMS
GENZYME CORPORATION $14.7904/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233522947 CMS
GlaxoSmithKline, LLC. $24.9804/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190856985 CMS
Novartis Pharmaceuticals Corporation $24.6304/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200157762 CMS
ABBVIE INC. $27.2603/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201760712 CMS
Mallinckrodt Hospital Products Inc. $17.1903/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211961184 CMS
Fidia Pharma USA Inc. $25.1503/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1185425494 CMS
Janssen Biotech, Inc. $20.8203/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174469269 CMS
ANI Pharmaceuticals, Inc. $17.7003/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248616429 CMS
GlaxoSmithKline, LLC. $15.7103/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190716817 CMS
ABBVIE INC. $19.3302/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201760710 CMS
Genentech USA, Inc. $23.8702/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211570631 CMS
Aurinia Pharma U.S., Inc. $26.8802/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249413048 CMS
ANI Pharmaceuticals, Inc. $18.6102/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248591039 CMS
Janssen Biotech, Inc. $7.6002/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174469108 CMS
KYOWA KIRIN, INC. $27.5401/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222079863 CMS
Novartis Pharmaceuticals Corporation $21.4601/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200157756 CMS
Novartis Pharmaceuticals Corporation $17.9601/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200157754 CMS
Janssen Biotech, Inc. $21.5301/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174465786 CMS
Novartis Pharmaceuticals Corporation $18.5801/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200157752 CMS
Amgen Inc. $14.2201/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227048718 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $17,434.26 243
PY2020 $8,423.03 185
PY2021 $9,171.75 170
PY2022 $21,396.90 194
PY2023 $12,841.74 121
PY2024 $9,795.52 130
PY2025 $4,774.24 134

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,598,958.59 13
PY2024 Recipient $20,454.58 2
PY2024 Principal investigator $339,199.22 6
PY2022 Principal investigator $1,986.00 1
PY2021 Principal investigator $12,378.33 6
PY2020 Recipient $2,615.39 9
PY2020 Principal investigator $85,777.32 10
PY2019 Principal investigator $91,192.23 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

13 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $2,225.00 10/07/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187880735
Principal investigator 1 Amgen Inc. $61,485.92 07/29/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS & RHEUMATOLOGY RESEARCH - GLENDALE
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246639191
Principal investigator 1 Amgen Inc. $677.60 07/28/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - GLENDALE - 5681 W BEVERLY LN
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639217
Principal investigator 1 Amgen Inc. $10,000.00 06/06/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246639267
Principal investigator 1 Amgen Inc. $131,252.51 04/18/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246639307
Principal investigator 1 Amgen Inc. $35,410.90 04/09/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH PLLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639245
Principal investigator 1 Amgen Inc. $147,259.28 03/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639291
Principal investigator 1 Eli Lilly and Company $2,011.70 02/25/2025 Non-covered Recipient Entity
AARA CLINICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187873189
Principal investigator 1 Amgen Inc. $13,147.86 01/29/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639229
Principal investigator 1 UCB SA $31,668.79 01/24/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246656988
Principal investigator 1 UCB SA $16,936.07 01/22/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - PHOENIX
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246657492
Principal investigator 1 Eli Lilly and Company $139,462.00 01/21/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187876441
Principal investigator 1 Amgen Inc. $2,007,420.96 01/03/2025 Non-covered Recipient Entity
ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - GLENDALE - 5681 W BEVERLY LN
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246639219